Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2 results

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, Agarwal P, Hull KL, Lyons KE, Johnson R, Stempien MJ. Pahwa R, et al. JAMA Neurol. 2017 Aug 1;74(8):941-949. doi: 10.1001/jamaneurol.2017.0943. JAMA Neurol. 2017. PMID: 28604926 Free PMC article. Clinical Trial.
IMPORTANCE: Medical treatment of levodopa-induced dyskinesia (LID) in Parkinson disease (PD) is an unmet need. OBJECTIVE: To evaluate the efficacy and safety of ADS-5102 (amantadine) extended-release 274 …
IMPORTANCE: Medical treatment of levodopa-induced dyskinesia (LID) in Parkinson disease (PD) is an …
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, Ehret R, Azulay JP, Isaacson S, Felt L, Stempien MJ. Oertel W, et al. Mov Disord. 2017 Dec;32(12):1701-1709. doi: 10.1002/mds.27131. Epub 2017 Aug 21. Mov Disord. 2017. PMID: 28833562 Free PMC article. Clinical Trial.
BACKGROUND: The treatment of levodopa-induced dyskinesia in Parkinson's disease (PD) is an unmet need with no approved drug therapy. OBJECTIVE: The purpose of this study was to investigate the efficacy and safety of 274 mg ADS-5 …
BACKGROUND: The treatment of levodopa-induced dyskinesia in Parkinson's disease (PD) is an unmet need wit …